Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus CYKLOKAPRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus CYKLOKAPRON.
AMINOCAPROIC ACID IN PLASTIC CONTAINER vs CYKLOKAPRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminocaproic acid is a lysine analog that binds to plasminogen and prevents its conversion to plasmin, thereby inhibiting fibrinolysis and stabilizing clots. It also inhibits plasmin directly at high doses.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
4-5 g IV over 1 hour followed by 1 g/h IV for 8 hours or until bleeding is controlled; max 30 g/24h.
1 g (10 mL) IV over 5-10 minutes every 6-8 hours; or 25-50 mg/kg/day IV divided every 6-8 hours. Oral: 1-1.5 g 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function. In end-stage renal disease, half-life may be prolonged to 7-10 hours.
Terminal elimination half-life: 2-3 hours (renal impairment extends to 10-20 hours).
Primarily renal (approximately 80-90% excreted unchanged in urine via glomerular filtration).
Renal: >95% as unchanged drug via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Antifibrinolytic
Antifibrinolytic